Georg Jaeschke

Basel, BS 4070, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Novel Macrocyclic NLRP3 Inhibitors.

Novel Macrocyclic NLRP3 Inhibitors.

Journal: Journal of medicinal chemistry

Published: November 25, 2024

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.

Journal: Journal of medicinal chemistry

Published: September 30, 2022

Chemical, Analytical and Pharmacokinetic Characterisation of RO7304898, an API Consisting of Two Rapidly Interconverting Diastereoisomers.

Chemical, Analytical and Pharmacokinetic Characterisation of RO7304898, an API Consisting of Two Rapidly Interconverting Diastereoisomers.

Journal: Pharmaceutical research

Published: November 30, 2021

News from DMCCB - Targeted Protein Degradation.

News from DMCCB - Targeted Protein Degradation.

Journal: Chimia

Published: January 17, 2019

mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex.

mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Published: August 02, 2017

Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods.

Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods.

Journal: British journal of clinical pharmacology

Published: April 18, 2017

Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences.

Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences.

Journal: Brain, behavior, and immunity

Published: March 24, 2016

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Journal: The Journal of pharmacology and experimental therapeutics

Published: February 11, 2015

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Journal: Journal of medicinal chemistry

Published: January 08, 2015

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.

Journal: Current opinion in pharmacology

Published: October 31, 2014

Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion.

Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion.

Journal: Nature neuroscience

Published: September 26, 2014

Homer1/mGluR5 activity moderates vulnerability to chronic social stress.

Homer1/mGluR5 activity moderates vulnerability to chronic social stress.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Published: June 04, 2014

Showing 1-12 of 17

Last Updated: 09/26/2026